Support Education Research
Please leave this field empty
Scleroderma Foundation
Homepage | Forward to a Friend | Make a Donation
eletter banner.jpg
eLetter #675 | September 9, 2016  

The Food and Drug Administration Bans Sale of Many Antibacterial Soaps, Saying Risks Outweigh Benefits

fdasoap.jpgThe Food and Drug Administration banned the sale of soaps containing certain antibacterial chemicals on Friday, saying industry had failed to prove they were safe to use over the long term or more effective than using ordinary soap and water.

Click here for more >>

Are You Prepared for an Emergency?

cdc-logo-1024x751.jpgIt is important that people with disabilities and their family members make plans to protect themselves in the event of disasters. In addition, first responders need to know how to work with people with disabilities to evacuate them safely and quickly. Emergency planners must ensure that shelters are accessible to people with a variety of disabilities.  The Centers for Disease Control and Prevention can help you get ready.

Click here for more >>

Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease (SSc-ILD)

Boehringer IngelheimBoehringer Ingelheim today announced that the European Commission (EC) and U.S. Food and Drug Administration (FDA) have granted Orphan Drug Designation to nintedanib for the treatment of systemic sclerosis (SSc, also known as scleroderma), including the associated interstitial lung disease (SSc-ILD).

Click here for the full release >>

Clinical Trials and Research Opportunities

Persons with Systemic Sclerosis Needed for Research Study

Researchers from the Universities of New Mexico and Michigan and the Medical University of South Carolina are seeing participants for a study to evaluate a self-management program for people with systemic sclerosis.  For more information about the study and eligibility requirements please contact Jennifer Serrano at or 734.232.2119.

STRATUS Clinical Research Study Looking for Patients with Systemic Sclerosis that Affects the Lungs

A clinical research study is looking at an investigational medication
that may slow the development of lung fibrosis (inflammation and scarring) associated with systemic sclerosis (SSc).  To help determine the safety and effectiveness of the investigational medication, they are looking for people who have SSc-associated interstitial lung disease (SSc-ILD) that affects the lungs (SSc-ILD) to take part in the study.  For more information about the study and eligibility requirements please contact Courtney Kinsey at or 214.818.7899. 

Quick Links
Contact Us
Become a Member
About Scleroderma
Calendar of Events
Online Chat

Actelion 2016 sponsor
2016 Bayer Logo
2016 Bronze National Sponsor Reata
2016 Gilead Silver Conference Sponsor
United Therapeutics Logo


Disclaimer: The Scleroderma Foundation in no way endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.

Powered by Blackbaud  Unsubscribe | Visit our web site | Contact Us | Donate
300 Rosewood Drive, Suite 105, Danvers, MA 01923 tel: 800-722-HOPE (4673)
© 2019 All rights reserved.